logo-loader

Trulieve’s 3Q results expected to reflect ongoing challenges facing cannabis MSOs

Published: 11:35 06 Nov 2023 EST

Trulieve Cannabis Corp. - Trulieve’s 3Q results expected to reflect ongoing challenges facing cannabis MSOs
Editorial credit: T. Schneider / Shutterstock.com

Trulieve Cannabis Corp. (CSE:TRUL) is expected to report a year-over-year decline in both its sales and profits when the cannabis company reports its third quarter financial results before the market opens on Thursday, November 9.

Continued weaker consumer spending due to inflationary pressures is expected to weigh on the Tallahassee, Florida multi-state operator (MSO)’s quarterly performance.

Additionally, U.S. cannabis companies are struggling amid lower prices, rising operating costs, and increased competition.

For the quarter ended September 30, 2023, Trulieve is expected to report a loss per share of $0.17, compared to earnings per share of $0.02 in the year-ago quarter.

Revenue is expected to decline from $300.7 million in the same period in 2022 to $269.47 million, Wall Street analysts forecast.

Trulieve shares traded down 1.7% at US$4.70 on Monday morning. The stock is down 35.4% in the year to date.

Contact the author at emily.jarvie@proactiveinvestors.com

Follow her on Twitter @emilyjjarvie

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

3 hours, 48 minutes ago